On April 24, 2026, the Japanese Industrial Standards Committee (JISC) published JIS T 0910:2026, mandating human factors (HF) and usability engineering validation per IEC 62366-1:2024 for all rehabilitation devices exported to Japan—including electric care beds, gait training systems, and neurofeedback systems. This update directly affects medical device manufacturers, exporters, and regulatory support providers serving the Japanese market, as it introduces a new compliance threshold with tangible impact on product registration timelines, documentation requirements, and post-market obligations.

Event Overview

The Japanese Industrial Standards Committee (JISC) released JIS T 0910:2026 on April 24, 2026. The standard fully adopts IEC 62366-1:2024, requiring human factors (HE) validation of user interfaces for all rehabilitation devices placed on the Japanese market. Covered products include electric care beds, gait training instruments, and neurofeedback systems. Compliance is mandatory from October 2026. During the transition period, existing JIS certifications remain valid for legacy submissions; however, all new applications must follow JIS T 0910:2026 and submit a complete Usability Engineering File.

Industries Affected

Medical Device Manufacturers (OEMs & Contract Manufacturers)

Manufacturers producing rehab devices for export to Japan will face revised pre-market submission requirements. Because JIS T 0910:2026 explicitly requires usability engineering validation aligned with IEC 62366-1:2024, design controls, risk management files, and verification protocols must now integrate HF testing early in development—not as a late-stage add-on. Impact includes extended development cycles, updated internal SOPs, and potential redesign of user interfaces or accompanying instructions for use (IFU).

Regulatory Affairs & Certification Service Providers

Third-party regulatory consultants and certification bodies supporting JIS submissions must revise their service offerings and audit checklists. As JIS T 0910:2026 mandates formal Usability Engineering Files—mirroring the structure and content expectations of IEC 62366-1:2024—providers must ensure assessors are trained on the 2024 edition’s updated definitions (e.g., ‘use error’ vs. ‘user error’), task analysis methodology, and summative evaluation criteria. This may affect service lead times and scope definitions for new projects.

Importers & Distributors of Rehab Devices in Japan

Japanese importers and distributors acting as marketing authorization holders (MAHs) under Japan’s PMD Act bear legal responsibility for conformity. With JIS T 0910:2026 entering force in October 2026, MAHs must verify that incoming shipments—especially those with new model numbers or updated software—include compliant Usability Engineering Files and evidence of summative usability testing. Failure to do so may delay MHLW approval or trigger post-market scrutiny during inspections.

What Relevant Enterprises or Practitioners Should Focus On and How to Respond

Monitor official guidance from MHLW and JISC on implementation interpretation

JIS T 0910:2026 is a technical standard—not legislation—but its enforcement relies on alignment with Japan’s Pharmaceutical and Medical Devices Act (PMD Act). Current more suitable understanding is that MHLW may issue supplementary notifications clarifying how usability evidence will be reviewed during PMDA reviews. Stakeholders should track updates via the MHLW website and JISC’s public bulletins, particularly any Q&A documents scheduled for release before July 2026.

Identify and prioritize high-volume or high-risk device categories for early validation

Analysis来看, electric care beds and gait training systems represent two of the most widely imported rehab device categories into Japan. From industry perspective, these devices typically feature complex user interfaces (e.g., multi-axis remote controls, touchscreen displays, safety interlocks), making them higher priority for early usability testing planning. Firms should map current product portfolios against JIS T 0910:2026’s scope definition and initiate HE planning for models scheduled for renewal or new application before October 2026.

Distinguish between policy signal and operational readiness

Observation shows that JIS T 0910:2026 reflects an ongoing harmonization trend—not an isolated change. Its adoption signals Japan’s continued alignment with ISO/IEC medical device standards, but does not yet indicate changes to clinical evaluation requirements or cybersecurity expectations (e.g., JIS X 6300 series). Companies should avoid conflating this update with broader regulatory shifts; instead, treat it as a focused documentation and validation upgrade for user interface safety.

Prepare usability engineering documentation and cross-functional alignment ahead of submission

Current best practice is to begin drafting core Usability Engineering File components—including use specification, hazard analysis linked to use errors, formative evaluation summaries, and summative test protocols—no later than Q3 2026 for submissions targeting October launch. Cross-functional coordination among R&D, QA, RA, and clinical teams is essential, as usability data must be traceable to risk management files (per JIS T 09001:2022) and design history records.

Editorial Perspective / Industry Observation

This update is better understood as a regulatory signal reinforcing Japan’s commitment to international harmonization—particularly with IEC 62366-1:2024—rather than an immediate operational disruption. Analysis来看, the six-month transition window (April–October 2026) suggests JISC and PMDA anticipate moderate readiness across the industry, but also implies limited flexibility for late-stage adjustments. From industry angle, the requirement elevates usability from a quality assurance activity to a formal, auditable design input—shifting emphasis toward proactive human-centered design, especially for devices used by elderly or cognitively impaired users. Continued attention is warranted not only for JIS T 0910:2026 itself, but also for related updates to JIS T 09001 (risk management) and JIS T 09005 (software lifecycle), which collectively shape Japan’s evolving medical device regulatory landscape.

In summary, JIS T 0910:2026 marks a formal step toward stricter human factors accountability for rehab devices in Japan—not a sudden departure, but a calibrated tightening of usability expectations. It reflects an internationally aligned, process-oriented evolution rather than a market access barrier. For stakeholders, the most rational interpretation is that this is a predictable, implementable update—best approached through structured documentation planning, targeted validation, and close monitoring of official implementation guidance.

Source: Japanese Industrial Standards Committee (JISC), JIS T 0910:2026 (published April 24, 2026).
Additional official interpretation materials from the Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) are pending and remain under observation.